Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial.
Cooper N, Ghanima W, Vianelli N, Valcárcel D, Yavaşoğlu İ, Melikyan A, Ruiz EY, Haenig J, Somenzi O, Lee J, Clark J, Zhang Y, Zaja F. Cooper N, et al. Among authors: valcarcel d. Am J Hematol. 2024 Jan;99(1):57-67. doi: 10.1002/ajh.27131. Epub 2023 Nov 28. Am J Hematol. 2024. PMID: 38014779 Free article. Clinical Trial.
Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms.
Jiménez M, Fernández-Naval C, Navarro V, Novoa S, Martinez-Gallo M, Medina D, Andrés C, Antón A, Peralta S, Pujadas G, Hernández C, Pagès C, Roldán E, Pumarola T, Gironella M, Ruiz-Camps I, Martínez-Gómez X, Valcárcel D, Hernández M, Bosch F, Crespo M, Esperalba J, Abrisqueta P. Jiménez M, et al. Among authors: valcarcel d. Am J Hematol. 2023 Aug;98(8):1204-1213. doi: 10.1002/ajh.26951. Epub 2023 May 8. Am J Hematol. 2023. PMID: 37151135 Free article.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM. Platzbecker U, et al. Among authors: valcarcel d. Lancet. 2024 Jan 20;403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048786 Clinical Trial.
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.
Haque T, Cadenas FL, Xicoy B, Alfonso-Pierola A, Platzbecker U, Avivi I, Brunner AM, Chromik J, Morillo D, Patel MR, Falantes J, Leitch HA, Germing U, Preis M, Lenox L, Lauring J, Brown RJ, Kalota A, Mehta J, Pastore F, Gu J, Mistry P, Valcárcel D. Haque T, et al. Among authors: valcarcel d. Leuk Res. 2023 Nov;134:107390. doi: 10.1016/j.leukres.2023.107390. Epub 2023 Sep 20. Leuk Res. 2023. PMID: 37776843 Clinical Trial.
Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.
Zugasti I, Lopez-Guerra M, Castaño-Díez S, Esteban D, Avendaño A, Pomares H, Perez A, García-Ávila S, Conejo IP, de la Fuente Montes C, Martínez-Roca A, Merchán B, Jiménez-Vicente C, Guijarro F, Álamo JR, Cortes-Bullich A, Torrecillas V, Mont L, Carcelero E, Riu G, Zamora L, Bargay J, Triguero A, Suarez-Lledó M, Salas MQ, López-Cadenas F, Ramos F, Xicoy B, Valcárcel D, Arnan M, Martínez C, Rovira M, Fernández-Avilés F, Díez-Campelo M, Esteve J, Díaz-Beyá M. Zugasti I, et al. Among authors: valcarcel d. Exp Hematol Oncol. 2025 Apr 26;14(1):61. doi: 10.1186/s40164-025-00652-5. Exp Hematol Oncol. 2025. PMID: 40287746 Free PMC article.
Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency.
Marin-Bejar O, Romero-Moya D, Rodriguez-Ubreva J, Distefano M, Lessi F, Aretini P, Liquori A, Castaño J, Kozyra E, Kotmayer L, Bueno C, Cervera J, Rodriguez-Gallego JC, Nomdedeu JF, Murillo-Sanjuán L, De Heredia CD, Pérez-Martinez A, López-Cadenas F, Martínez-Laperche C, Dorado-Herrero N, Marco FM, Prósper F, Menendez P, Valcárcel D, Ballestar E, Bödör C, Bigas A, Catalá A, Wlodarski MW, Giorgetti A. Marin-Bejar O, et al. Among authors: valcarcel d. Haematologica. 2023 Sep 1;108(9):2551-2557. doi: 10.3324/haematol.2022.282305. Haematologica. 2023. PMID: 36815365 Free PMC article. No abstract available.
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes.
Berastegui N, Ainciburu M, Romero JP, Garcia-Olloqui P, Alfonso-Pierola A, Philippe C, Vilas-Zornoza A, San Martin-Uriz P, Ruiz-Hernández R, Abarrategi A, Ordoñez R, Alignani D, Sarvide S, Castro-Labrador L, Lamo-Espinosa JM, San-Julian M, Jimenez T, López-Cadenas F, Muntion S, Sanchez-Guijo F, Molero A, Montoro MJ, Tazón B, Serrano G, Diaz-Mazkiaran A, Hernaez M, Huerga S, Bewicke-Copley F, Rio-Machin A, Maurano MT, Díez-Campelo M, Valcarcel D, Rouault-Pierre K, Lara-Astiaso D, Ezponda T, Prosper F. Berastegui N, et al. Among authors: valcarcel d. Nat Commun. 2022 Dec 9;13(1):7619. doi: 10.1038/s41467-022-35192-7. Nat Commun. 2022. PMID: 36494342 Free PMC article.
A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS.
Searle E, Cluzeau T, O'Nions J, Recher C, Gyan E, Morillo D, Esteve J, Kulasekararaj A, Raffoux E, Walter HS, Pigneux A, Valcárcel D, Daskalakis N, Bussolari J, Pietsch EC, Kuduk S, Bush T, Zhang X, Philippar U, Oluwasanjo A, Bradford K, Miller J, Van Bogaert C, Curtis M, Chang SY, Guttke C, Gaj S, Pearson R, Murphy J, van Dijck W, Alfonso Piérola A. Searle E, et al. Among authors: valcarcel d. Br J Haematol. 2025 Jul 1. doi: 10.1111/bjh.20224. Online ahead of print. Br J Haematol. 2025. PMID: 40598790 No abstract available.
Divertor shaping with neutral baffling as a solution to the tokamak power exhaust challenge.
Verhaegh K, Harrison J, Moulton D, Lipschultz B, Lonigro N, Osborne N, Ryan P, Theiler C, Wijkamp T, Brida D, Cowley C, Derks G, Doyle R, Federici F, Kool B, Février O, Hakola A, Henderson S, Reimerdes H, Thornton A, Vianello N, Wischmeier M, Xiang L; EUROfusion Tokamak Exploitation Team; MAST Upgrade Team. Verhaegh K, et al. Commun Phys. 2025;8(1):215. doi: 10.1038/s42005-025-02121-1. Epub 2025 May 23. Commun Phys. 2025. PMID: 40417628 Free PMC article.
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.
Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Pozharskaya V, Rose S, Keeperman K, Lai Y, Kalsekar S, Aggarwal B, Miteva D, Valcárcel D, Fenaux P, Shortt J, Della Porta MG, Platzbecker U. Garcia-Manero G, et al. Among authors: valcarcel d. Adv Ther. 2025 Jul;42(7):3576-3589. doi: 10.1007/s12325-025-03208-5. Epub 2025 May 16. Adv Ther. 2025. PMID: 40377899 Free PMC article. Clinical Trial.
183 results